Information Provided By: 
Fly News Breaks for August 8, 2018
HAE
Aug 8, 2018 | 08:08 EDT
Jefferies analyst Anthony Petrone raised his price target for Haemonetics to $125 following the company's Q1 results. The plasma growth surge was driven largely by an uptick in volumes that is expected to continue, Petrone tells investors in a research note. The analyst sees upside to over $150 per share on the "rapid uptake of NexSys on favorable terms." He keeps a Buy rating on Haemonetics.
News For HAE From the Last 2 Days
There are no results for your query HAE
